Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
CStone Pharmaceuticals clinical trials
The registry lists 28 studies whose lead sponsor is CStone Pharmaceuticals. 3 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 1, 2026.
Keep track of what changes. Save the CStone Pharmaceuticals studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to CStone Pharmaceuticals.
- CStone Pharmaceuticals28 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 28 of 28.
- A Phase I/II Study of CS2009 in Participants With Advanced Solid TumorsRecruitingNCT06741644Phase 1/2
- A Phase I Study of CS5007 in Participants With Advanced Solid TumorsRecruitingNCT07622524Phase 1
- Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell LymphomaNot yet recruitingNCT05700448Phase 3
- A Study of CS5001 in Patients With Advanced Solid Tumors and LymphomasSuspendedNCT05279300Phase 1
- A Study of CS1001 in Subjects With Stage IV Non-Small Cell Lung CancerCompletedNCT03789604Phase 3
- A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular CarcinomaActive, not recruitingNCT04194775Phase 3
- A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung CancerActive, not recruitingNCT05297890Phase 2
- Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real WorldCompletedNCT05381753
- A Study of CS3006 in Subjects with Locally Advanced or Metastatic Solid TumorsCompletedNCT03516123Phase 1
- A Study of CS1002 in Subjects with Advanced Solid TumorsCompletedNCT03523819Phase 1
- A Study of CS1001 in Subjects with Advanced Solid TumorsCompletedNCT03744403Phase 1
- A Study of CS1001 in Subjects With Relapsed or Refractory Extranodal Natural Killer/ T Cell Lymphoma(ENKTL)CompletedNCT03595657Phase 2
- Safety and Tolerability Evaluation of Low-dose Radiation in Combination With CS1001 in Relapsed SCLC PatientsCompletedNCT04421352Phase 1
- A Study of CS1001 in Subjects With Gastric Adenocarcinoma or Gastro-Esophageal Junction AdenocarcinomaCompletedNCT03802591Phase 3
- A Study of CS1001 in Subjects With Esophageal Squamous Cell CarcinomaCompletedNCT04187352Phase 3
- A Study of CS1001 in Subjects With Stage III Non-Small Cell Lung CancerCompletedNCT03728556Phase 3
- A Study of CS3007 in Subjects With Gastrointestinal Stromal TumorCompletedNCT04254939Phase 1/2
- A China Bridging Study of Ivosidenib in r/r AML Subjects With an IDH1 MutationCompletedNCT04176393Phase 1
- A Phase Ib/II Study of Fisogatinib(BLU-554) in Subjects With Hepatocellular CarcinomaCompletedNCT04194801Phase 1/2
- A Study of CS1003 in Subjects With Advanced Solid Tumors or LymphomasCompletedNCT03809767Phase 1
- A Study of CS1001 in Subjects With Relapsed or Refractory Classical Hodgkin LymphomaCompletedNCT03505996Phase 2
- A Phase Ia/Ib Study of CS1001 in Subjects With Advanced Solid TumorsCompletedNCT03312842Phase 1
- A Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid TumorsCompletedNCT04200404Phase 1/2
- A Study of CS3005 in Advanced Solid TumorsCompletedNCT04233060Phase 1
- A Study of CS1003 in Subjects With Advanced Solid TumorsCompletedNCT03475251Phase 1
- A Study of CS3002 in Subjects With Advanced Solid TumorsTerminatedNCT04162301Phase 1
- A Phase I Study of CS1002 in Subjects With Advanced Solid TumorsCompletedNCT04338724Phase 1
- Study of CS3006 in Subjects With Locally Advanced or Metastatic Solid TumorsCompletedNCT03736850Phase 1